Vistin Pharma ASA Cash Flow Conversion Efficiency

Latest as of March 2026: -0.010x

Vistin Pharma ASA cash flow conversion efficiency. Based on the latest financial reports, Vistin Pharma ASA (VISTN) has a cash flow conversion efficiency ratio of -0.010x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-3.67 Million ≈ $-386.40K USD) by net assets (Nkr350.31 Million ≈ $36.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Vistin Pharma ASA (2016–2025)

Cash flow conversion efficiency of Vistin Pharma ASA from 2016 to 2025. This chart illustrates how Vistin Pharma ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View VISTN share price today for real-time trading data and today's change.

Vistin Pharma ASA Cash Flow Conversion Ratio Explained

Vistin Pharma ASA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Vistin Pharma ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vistin Pharma ASA ranked by their cash flow conversion efficiency. Also see market value of Vistin Pharma ASA for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Hyosung Itx KO:094280	0.371x
La Kaffa International Co Ltd TWO:2732	0.048x
Merit Turizm Yatirim ve Isletme AS IS:MERIT	0.006x
Grange Resources Ltd AU:GRR	0.038x
Yusin Holding Corp TW:4557	0.042x
Centrica PLC LSE:CNA	0.012x
ReFuels N.V. OL:REFL	N/A
Nuveen California Select Tax Free Income Closed Fund NYSE:NXC	-0.014x

Annual Cash Flow Conversion Efficiency for Vistin Pharma ASA (2016–2025)

The table below shows the annual cash flow conversion efficiency of Vistin Pharma ASA from 2016 to 2025. Review cash generation quality of Vistin Pharma ASA to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Nkr328.81 Million ≈ $34.60 Million	Nkr78.04 Million ≈ $8.21 Million	0.237x	-31.89%
2024-12-31	Nkr309.53 Million ≈ $32.57 Million	Nkr107.86 Million ≈ $11.35 Million	0.348x	+24.15%
2023-12-31	Nkr322.77 Million ≈ $33.96 Million	Nkr90.59 Million ≈ $9.53 Million	0.281x	+964.87%
2022-12-31	Nkr273.26 Million ≈ $28.76 Million	Nkr-8.87 Million ≈ $-933.17K	-0.032x	-165.44%
2021-12-31	Nkr275.89 Million ≈ $29.03 Million	Nkr13.68 Million ≈ $1.44 Million	0.050x	+109.27%
2020-12-31	Nkr272.40 Million ≈ $28.66 Million	Nkr-145.73 Million ≈ $-15.34 Million	-0.535x	-1267.99%
2019-12-31	Nkr413.40 Million ≈ $43.50 Million	Nkr18.93 Million ≈ $1.99 Million	0.046x	+140.47%
2018-12-31	Nkr348.85 Million ≈ $36.71 Million	Nkr-39.48 Million ≈ $-4.15 Million	-0.113x	-243.02%
2017-12-31	Nkr120.16 Million ≈ $12.64 Million	Nkr9.51 Million ≈ $1.00 Million	0.079x	-72.57%
2016-12-31	Nkr186.61 Million ≈ $19.64 Million	Nkr53.84 Million ≈ $5.67 Million	0.288x	--

About Vistin Pharma ASA

OL:VISTN Norway Drug Manufacturers - Specialty & Generic

Market Cap

$85.86 Million

Nkr815.94 Million NOK

Market Cap Rank

#19584 Global

#175 in Norway

Share Price

Nkr18.40

Change (1 day)

-1.08%

52-Week Range

Nkr18.00 - Nkr23.20

All Time High

Nkr28.06